Altimmune (ALT) Equity Average (2011 - 2026)

Altimmune (ALT) has 16 years of Equity Average data on file, last reported at $254.4 million in Q1 2026.

• Equity Average for Q1 2026 came in at $254.4 million, up 91.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $254.4 million (up 91.55% YoY), and the FY2025 annual result was $174.2 million, up 9.7% from the prior year.
• Equity Average rose to $254.4 million in Q1 2026 per ALT's latest filing, from $205.2 million in the prior quarter.
• Over five years, Equity Average peaked at $254.4 million in Q1 2026 and troughed at $128.4 million in Q4 2024.
• A 5-year average of $175.7 million and a median of $173.5 million in 2025 frame the typical range for Equity Average.
• The sharpest annual moves came in 2025 and 2026: Equity Average fell 27.62% in 2025, then surged 91.55% in 2026.
• A 5-year view of Equity Average shows it stood at $195.2 million in 2022, then retreated by 11.74% to $172.2 million in 2023, then dropped by 25.43% to $128.4 million in 2024, then soared by 59.8% to $205.2 million in 2025, then grew by 23.97% to $254.4 million in 2026.
• Business Quant data shows ALT's Equity Average at $254.4 million in Q1 2026, $205.2 million in Q4 2025, and $173.5 million in Q3 2025.